BioSpace News Archive

The BioSpace team is recording from San Francisco as they bring you the the latest highlights from Day 2 at JPM2024.

Faron Pharmaceuticals Ltd. announced that the first patient has been dosed in Phase 2 of the BEXMAB trial that evaluates the safety and efficacy of bexmarilimab, in combination with standard of care in patients with hypomethylating agents -refractory or relapsed myelodysplastic syndrome, an aggressive myeloid leukemia with very few treatment options.

BioArctic AB’s partner Eisai announced that Leqembi® has been approved in China as a treatment for mild cognitive impairment due to Alzheimer’s disease and mild AD dementia.

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced preliminary unaudited fourth quarter and full year 2023 revenue and established its 2024 financial guidance.

ICON plc, a world-leading clinical research organization powered by healthcare intelligence, announced its financial guidance for the year ending December 31, 2024.

Cutera, Inc., a leading provider of aesthetic and dermatology solutions, announced certain preliminary, unaudited financial results for the year ended December 31, 2023.

Ultima Genomics, a developer of a revolutionary new ultra-high throughput sequencing architecture, and Quest Diagnostics (NYSE: DGX), the nation’s leading provider of diagnostic information services, today announced a collaboration involving Ultima’s next generation sequencing (NGS) technology in oncology and other clinical areas.

AiCuris Anti-infective Cures AG announced that it has received milestone payments in the amount of EUR €15 million from its licensing partner MSD ) following EMA approval for the first-in-class antiviral agent PREVYMIS® for the prophylaxis of CMV disease after kidney transplant in Donor CMV-seropositive/Recipient CMV-seronegative patients at high risk.

SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the issuance of U.S. Patent No. 11,866,730 with broad claims directed to methods of using the Selective Cytopheretic Device (SCD) to treat subjects with inflammatory conditions and to process activated leukocytes and platelets.

Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced preliminary unaudited fourth quarter 2023 net sales of approximately $200.3 million, an increase of 63.8% on a reported basis and 62.8% on a constant currency basis versus fourth quarter 2022.